May 1, 2010

Effect of Valsartan on the Incidence of Diabetes and Cardiovascular Events

.   .   

9306 patients with IGTT and established cardiovascular disease or cardiovascular risk factors were randomized to receive valsartan (up to 160 mg daily) or placebo (and nateglinide or placebo) in addition to lifestyle modification. After a median 5 year follow-up, there was a relative reduction of 14% in the incidence of diabetes in the valsartan group. However, there was no reduction in the rate of cardiovascular events.

See the accompanying editorial “Navigating the choices for diabetes prevention.”

Related Articles:

Diabetes, RAS Blockade
  • Dr. G. Summers

    Unlike the HOPE study, this study failed to show any reduction in cardiovascular events. This could be explained by the high rates of loss to follow-up (13%), use of off-study ACE inhibitors or ARBs among participants assigned to placebo (24%), and nonadherence to valsartan (34% by study end).